John Renger
Chief Tech/Sci/R&D Officer chez CEREVEL THERAPEUTICS HOLDINGS, INC.
Fortune : 269 260 $ au 31/03/2024
Profil
Actuellement, John Renger est directeur scientifique de Cerevel Therapeutics Holdings, Inc. Dans le passé, le Dr Renger a été vice-président associé chez Merck & Co., Inc. et vice-président de la recherche et du développement chez Imbrium Therapeutics LP. Il a obtenu un doctorat et un diplôme de premier cycle à l'Université de l'Iowa.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
07/02/2024 | 6 370 ( 0,00% ) | 269 260 $ | 31/03/2024 |
Postes actifs de John Renger
Sociétés | Poste | Début |
---|---|---|
CEREVEL THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Anciens postes connus de John Renger
Sociétés | Poste | Fin |
---|---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Corporate Officer/Principal | 01/04/2018 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/08/2016 |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Chief Tech/Sci/R&D Officer | - |
Formation de John Renger
University of Iowa | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |